Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Mandatory press release to disclose receipt of Nasdaq Staff Determination Letter.
-
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
-
HCW Biologics signed license agreement with WY Biotech
-
Press release for Q3 2024 business highlights and financial results
-
Results of Q2 2024, including settlement of long-running arbitration.
-
Results of Q2 2024, including settlement of long-running arbitration.
-
Earning release for Q1 2024
-
Q4 and Year End Earnings Release and Business Highlights
-
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
-
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.